multiQure

MultiQure is a Frankfurt-based, clinical-stage biotechnology company focused on developing multi-target therapies to address complex diseases such as viral infections and cancer. The company's approach centers on the belief that targeting a single pathway is often insufficient for durable cures, leading them to design agents that act on multiple disease-relevant targets simultaneously. Their lead candidate, MQ-101, is currently undergoing Phase 2 clinical evaluation for COVID-19, demonstrating the company's ability to rapidly translate research into clinical applications. MultiQure is also developing MQ-201, a preclinical program aimed at overcoming resistance mechanisms in oncology. By leveraging a network of clinical partners and a proprietary design strategy, MultiQure aims to redefine treatment paradigms for high-unmet-need indications.